Related Experiment Video
Updated: Jul 7, 2026
07:08
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
Clinical proteomics in neurodegenerative disorders
H Zetterberg1, U Rüetschi, E Portelius
1Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at Göteborg University, Sweden. henrik.zetterberg@clinchem.gu.se
Acta Neurologica Scandinavica
|February 19, 2008
Summary
Early diagnosis of neurodegenerative diseases is crucial. Biomarkers, particularly in clinical neuroproteomics, offer hope for identifying conditions like Alzheimer's disease and Parkinson's disease sooner.
Area of Science:
- Neuroscience
- Biomarker Discovery
- Proteomics
Background:
- Neurodegenerative disorders involve neuronal impairment and death, with limited regenerative capacity.
- Early diagnosis is critical for effective treatment, but early symptoms are often subtle and difficult to detect.
- Existing biomarkers for Alzheimer's disease (AD) aid early detection, but more are needed for AD and other neurodegenerative conditions.
Purpose of the Study:
- To review recent advancements in clinical neuroproteomics for biomarker discovery.
- To provide an overview of commonly used techniques in neuroproteomics.
- To highlight major clinically relevant findings from neuroproteomic research.
Main Methods:
- Review of recent literature on clinical neuroproteomics.
- Analysis of techniques used in biomarker discovery for neurodegenerative diseases.
- Synthesis of clinically relevant findings from neuroproteomic studies.
Main Results:
- Clinical neuroproteomics has expanded significantly, offering new avenues for biomarker identification.
- Established biomarkers for Alzheimer's disease include total tau, hyperphosphorylated tau, and beta-amyloid.
- Ongoing research aims to identify novel biomarkers for Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis.
Conclusions:
- Biomarkers are essential for early diagnosis and effective intervention in neurodegenerative disorders.
- Clinical neuroproteomics is a rapidly advancing field with the potential to revolutionize diagnosis.
- Continued research is vital to develop and validate biomarkers for a wider range of neurodegenerative diseases.
Related Concept Videos
01:33Proteomics
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
01:13The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...